Bisphosphonates and osteonecrosis of the jaws: Science and rationale

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology

Volumn 104, Issue 2, 2007, Pages 186-193

  Gutta, Rajesh ^a   Louis, Patrick J ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ARTICLE; BONE NECROSIS; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG CONTRAINDICATION; DRUG DESIGN; HUMAN; JAW DISEASE; ORAL SURGERY; PATHOPHYSIOLOGY;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG DESIGN; HUMANS; JAW DISEASES; ORAL SURGICAL PROCEDURES; OSTEONECROSIS;

EID: 34447251281     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tripleo.2006.12.004     Document Type: Article

References (70)

1. Bouquot J.E., and McMahon R.E. Neuropathic pain in maxillofacial osteonecrosis. J Oral Maxillofac Surg 58 (2000) 1003-1020
2. Assouline-Dayan Y., Chang C., Greenspan A., Shoenfeld Y., and Gershwin M.E. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum 32 (2002) 94-124
3. Gruppo R., Glueck C.J., McMahon R.E., Bouquot J., Rabinovich B.A., Becker A., et al. The pathophysiology of alveolar osteonecrosis of the jaw: anticardiolipin antibodies, thrombophilia, and hypofibrinolysis. J Lab Clin Med 127 (1996) 481-488
4. Menschutkin N. Ueber die Einwirkung des Chloracetyls auf phosphorige Säure. Ann Chem Pharm 133 (1865) 317-320
5. Francis M.D., Russell R.G.G., and Fleisch H. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 165 (1969) 1264-1266
6. Fleisch H., Russell R.G.G., and Straumann F. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature 212 (1966) 901-903
7. Fleisch H., Russell R.G.G., Bisaz S., Muhlbauer R.C., and Williams D.A. The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur J Clin Invest 1 (1970) 12-18
8. Fleisch H., Russell R.G.G., and Francis M.D. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165 (1969) 1262-1264
9. Schenk R., Eggli P., Fleisch H., and Rosini S. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int 38 (1986) 342-349
10. Conte P., and Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 9 Suppl 4 (2004) 28-37
11. Bisaz S., Jung A., and Fleisch H. Uptake by bone of pyrophosphate, diphosphonates and their technetium derivatives. Clin Sci Mol Med 54 (1978) 265-272
12. Kasting G.B., and Francis M.D. Retention of etidronate in human, dog, and rat. J Bone Miner Res 7 (1992) 513-522
13. Reitsma P.H., Bijvoet O.L.M., Verlinden-Ooms H., and van der Wee-Pals L.J. Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxy-propylidene)-1,1-bisphosphonate (APD) in rats. Calcif Tissue Int 32 (1980) 145-157
14. Lehenkari P.P., Kellinsalmi M., Napankangas J.P., Ylitalo K.V., Monkkonen J., Rogers M.J., et al. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol 61 (2002) 1255-1262
15. Reszka A.A., and Rodan G.A. Mechanism of action of bisphosphonates. Curr Osteoporos Rep 1 (2003) 45-52
16. Murakami H., Takahashi N., Sasaki T., Udagawa N., Tanaka S., Nakamura I., et al. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 17 (1995) 137-144
17. Body J.J. Rationale for the use of bisphosphonates in osteoblastic and osteolytic bone lesions. Breast 12 Suppl 2 (2003) S37-S44
18. Fournier P., Boissier S., Filleur S., Guglielmi J., Cabon F., Colombel M., et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62 (2002) 6538
19. Zhang F.L., and Casey P.J. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 65 (1996) 241-249
20. Hall A. Rho GTPases and the actin cytoskeleton. Science 279 (1998) 509-514
21. Sato M., Grasser W., Endo N., Akins R., Simmons H., Thompson D.D., et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88 (1991) 2095-2105
22. John A., and Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 7 (2001) 14-23
23. Hellstein J.W., and Marek C.L. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century?. J Oral Maxillofac Surg 63 (2005) 682-689
24. Niskikawa M., Akatsu T., Katayama Y., Yasutomo Y., Kado S., Kugal N., et al. Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone 18 (1996) 9-14
25. Cecchini M.G., Felix R., Fleisch H., and Cooper P.H. Effect of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages. J Bone Miner Res 2 (1987) 135-142
26. + ATPase. J Bone Miner Res 11 (1996) 1498-1507
27. Felix R., Russell R.G.G., and Fleisch H. The effect of several diphosphonates on acid phosphohydrolases and other lysosomal enzymes. Biochim Biophys Acta 429 (1976) 429-438
28. Suda T., Nakamura I., Jimi E., and Takahashi N. Regulation of osteoclast function. J Bone Miner Res 12 (1997) 869-879
29. Russell R.G., and Rogers M.J. Bisphosphonates: from the laboratory to the clinic and back again. Bone 25 (1999) 97-106
30. Tassone P., Tagliaferri P., Viscomi C., Palmieri C., Caraglia M., D'Alessandro A., et al. Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer 88 (2003) 1971-1978
31. Senaratne S.G., Mansi J.L., and Colston K.W. The bisphosphonate zoledronic acid impairs Ras membrane localisation and induces cytochrome c release in breast cancer cells. Br J Cancer 86 (2002) 1479-1486
32. Twiss I.M., Pas O., Ramp-Koopmanschap W., Den Hartigh J., and Vermeij P. The effects of nitrogen-containing bisphosphonates on human epithelial (Caco-2) cells, an in vitro model for intestinal epithelium. J Bone Miner Res 14 (1999) 784-791
33. Mundy G.R., Yoneda T., and Hiraga T. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment. Semin Oncol 28 (2001) 35-44
34. Bassett C.A.L., Donath A., Macagno F., Preisig R., Fleisch H., and Francis M.D. Diphosphonates in the treatment of myositis ossificans. Lancet 2 (1969) 845
35. Bijvoet O., Fleisch H., Canfield R.E., and Russell R.G.G. Bisphosphonates on bone (1995), Elsevier, Amsterdam
36. Briner W.W., Francis M.D., and Widder J.S. The control of dental calculus in experimental animals. Int Dent J 21 (1971) 61-73
37. Mühlemann H.R., Bowles D., Schatt A., and Bernimoulin J.P. Effect of diphosphonate on human supragingival calculus. Helv Odont Acta 14 (1970) 31-33
38. Sturzenberger O.P., Swancar J.R., and Reiter G. Reduction of dental calculus in humans through the use of a dentifrice containing a crystal-growth inhibitor. J Periodontol 42 (1971) 416-419
39. Delmas P.D., and Meunier P.J. The management of Paget's disease of bone. N Engl J Med 336 (1997) 558-6
40. McCloskey E.V., MacLennan I.C.M., Drayson M., Chapman C., Dunn J., Kanis J.A., and MRC Working Party on Leukaemia in Adults. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br J Haematol 100 (1998) 317-325
41. Mundy G.R., and Yoneda T. Bisphosphonates as anticancer drugs. N Engl J Med 339 (1998) 398-400
42. Ralston S.H., Gallacher S.J., Patel U., Dryburgh F.J., Fraser W.D., Cowan R.A., et al. Comparison of 3 bisphosphonates in cancer-associated hypercalcaemia. Lancet 2 (1989) 1180-1182
43. Keen R.W., and Spector T.D. Alendronate: a new bisphosphonate for the treatment of osteoporosis. Br J Clin Pract 50 4 (1996) 211-217 Jun
44. Reginster J.Y., Lecart M.P., Deroisy R., Sarlet N., Denis D., Ethgen D., et al. Prevention of postmenopausal bone loss by tiludronate. Lancet 2 (1989) 1469-1471
45. Kramsch D.M., and Chan C.T. The effect of agents interfering with soft tissue calcification and cell proliferation on calcific fibrous-fatty plaques in rabbits. Circ Res 42 (1978) 562-571
46. Caraglia M., Santini D., Marra M., Vincenzi B., Tonini G., and Budillon A. A Emerging anticancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer 13 (2006) 7-26
47. Coleman R.E., Major P., Lipton A., Brown J.E., Lee K.A., Smith M., et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23 (2005) 4925-4935
48. Tarassoff P., and Csermak K. Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg 61 (2003) 1238-1239
49. Starck W.J., and Epker B.N. Failure of osseointegrated dental implants after diphosphonate therapy for osteoporosis: a case report. Int J Oral Maxillofac Implants 10 (1995) 74-78
50. Novartis Pharmaceuticals Co. [letter to health care professionals]. Updated safety: possible relationship of Aredia (pamidronate disodium) and/or Zometa (zoledronic acid) with osteonecrosis of the jaw (2004), Health Canada, Ottawa. http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/aredia_zometa_hpc_e.html Nov. Available at: www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/aredia_zometa_hpc_e.html. (accessed May 26, 2005).
51. Zervas K., Verrou E., Teleioudis Z., Vahtsevanos K., Banti A., Mihou D., et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 134 (2006) 620-623
52. Bamias A., Kastritis E., Bamia C., Moulopoulos L.A., Melakopoulos I., Bozas G., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23 (2005) 8580-8587
53. Badros A., Weikel D., Salama A., Goloubeva O., Schneider A., Rapoport A., et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24 (2006) 945-952
54. Larsson A. The short-term effects of high doses of ethylene-1-hydroxy-1,1-diphosphonates upon early dentin formation. Calcif Tissue Res 16 (1974) 109-127
55. Weile V., Josephsen K., and Fejerskov O. Effects of single doses of 1-hydroxyethylidene-1,1-bisphosphonate (HEBP) on the mineralizing front of rat incisor enamel: a microradiographic and scanning electron microscopic study. Arch Oral Biol 35 (1990) 857-867
56. Alatli I., and Hammarström L. Root surface defects in rat molar induced by 1-hydroxyethylidene-1,1-bisphosphonate. Acta Odontol Scand 54 (1996) 59-65
57. Flora L., Hassing G.S., Cloyd G.G., Bevan J.A., Parfitt A.M., and Villanueva A.R. Comparative skeletal effects of two diphosphonates in dogs. Metab Bone Dis Rel Res 2 (1980) 389-407
58. Hillner B.E., Ingle J.N., Chlebowski R.T., Gralow J., Yee G.C., Janjan N.A., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21 (2003) 4042-4057
59. Guarneri V., Donati S., Nicolini M., Giovannelli S., D'Amico R., and Conte P.F. Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years. Oncologist 10 (2005) 842-848
60. Legge T. Industrial maladies (1934), Oxford University Press, London
61. Phosphorus necrosis under control. [Editor's Note]. Br Dent J 76 (1944) 343
62. Zigic T.M., Marcous C., Hungerford D.S., Dansereau J.V., and Stevens M.B. Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosis. Am J Med 79 (1985) 596
63. Storm T., Steiniche T., Thamsborg G., and Melsen F. Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis. J Bone Miner Res 8 (1993) 199-208
64. Balena R., Toolan B.C., Shea M., Markatos A., Myers E.R., Lee S.C., et al. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 92 (1993) 2577-2586
65. Damato K, Gralow J, Hoff A, Huryn J, Marx RE, Ruggiero S, et al. Available at: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4095B2_02_12-Novartis-Zometa-App-11.pdf. (Accessed May 4, 2005).
66. AAOMS Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws. Available at: http://aaoms.org/docs/position_papers/osteonecrosis.pdf. (Accessed October 5, 2006).
67. Coxon F.P., Helfrich M.H., Larijani B., Muzylak M., Dunford J.E., Marshall D., et al. Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages. J Biol Chem 276 (2001) 48213-48222
68. Caraglia M., Addeo R., Costanzo R., Montella L., Faiola V., Marra M., et al. Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours. Cancer Chemother Pharmacol 12 (2005) 1-6
69. McClung M., Lewiecki E.M., Cohen S.B., Bolognese M.A., Woodson G.C., Moffett A.H., et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354 (2006) 821-831
70. Body J.J., Facon T., Coleman R.E., Lipton A., Geurs F., Fan M., et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 12 (2006) 1221-1228